Development and validation of a physiology-based model for the prediction of pharmacokinetics/toxicokinetics in rabbits

The environmental fates of pharmaceuticals and the effects of crop protection products on non-target species are subjects that are undergoing intense review. Since measuring the concentrations and effects of xenobiotics on all affected species under all conceivable scenarios is not feasible, standard laboratory animals such as rabbits are tested, and the observed adverse effects are translated to focal species for environmental risk assessments. In that respect, mathematical modelling is becoming increasingly important for evaluating the consequences of pesticides in untested scenarios. In particular, physiologically based pharmacokinetic/toxicokinetic (PBPK/TK) modelling is a well-established methodology used to predict tissue concentrations based on the absorption, distribution, metabolism and excretion of drugs and toxicants. In the present work, a rabbit PBPK/TK model is developed and evaluated with data available from the literature. The model predictions include scenarios of both intravenous (i.v.) and oral (p.o.) administration of small and large compounds. The presented rabbit PBPK/TK model predicts the pharmacokinetics (Cmax, AUC) of the tested compounds with an average 1.7-fold error. This result indicates a good predictive capacity of the model, which enables its use for risk assessment modelling and simulations.

[1]  J. G. Hengstler,et al.  Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH) , 2008, Archives of Toxicology.

[2]  Malcolm Rowland,et al.  PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. , 2011, Journal of pharmaceutical sciences.

[3]  Thomas Hartung,et al.  The dawning of a new age of toxicology. , 2008, ALTEX.

[4]  Anna M. Wu,et al.  A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn) , 2005, Annals of Biomedical Engineering.

[5]  William J Jusko,et al.  Moving from basic toward systems pharmacodynamic models. , 2013, Journal of pharmaceutical sciences.

[6]  Jingjing Yu,et al.  Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification , 2015, Drug Metabolism and Disposition.

[7]  Walter Schmitt,et al.  A physiological model for the estimation of the fraction dose absorbed in humans. , 2004, Journal of medicinal chemistry.

[8]  Walter Schmitt,et al.  Whole body physiologically-based pharmacokinetic models: their use in clinical drug development , 2008 .

[9]  M. Bonati,et al.  Pharmacokinetics of theophylline and its metabolites in rabbits , 1985, European Journal of Drug Metabolism and Pharmacokinetics.

[10]  Mirjam N Trame,et al.  Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network , 2016, CPT: pharmacometrics & systems pharmacology.

[11]  Melvin E Andersen,et al.  Toxicokinetic modeling and its applications in chemical risk assessment. , 2003, Toxicology letters.

[12]  W. Russell,et al.  Ethical and Scientific Considerations Regarding Animal Testing and Research , 2011, PloS one.

[13]  Harvey J Clewell,et al.  PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop. , 2014, Regulatory toxicology and pharmacology : RTP.

[14]  M. Block Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps , 2015, Expert opinion on drug metabolism & toxicology.

[15]  M. Fujii,et al.  Pharmacokinetics of acetaminophen from rapidly disintegrating compressed tablet prepared using microcrystalline cellulose (PH-M-06) and spherical sugar granules. , 2001, Chemical & pharmaceutical bulletin.

[16]  Walter Schmitt,et al.  Physiology-based pharmacokinetic modeling: ready to be used. , 2004, Drug discovery today. Technologies.

[17]  T. Kararli Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals , 1995, Biopharmaceutics & drug disposition.

[18]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[19]  A. Wolc,et al.  Pharmacokinetics and ocular disposition of paracetamol and paracetamol glucuronide in rabbits with diabetes mellitus induced by alloxan , 2012, Pharmacological reports : PR.

[20]  J. Dressman,et al.  Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. , 2011, Journal of pharmaceutical sciences.

[21]  Ioannis P. Androulakis,et al.  Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine , 2016, Journal of Pharmacokinetics and Pharmacodynamics.

[22]  A. El‐Yazigi,et al.  Theophylline absorption and disposition in rabbits: oral, intravenous, and concentration-dependent kinetic studies. , 1981, Journal of pharmaceutical sciences.

[23]  D. Mager,et al.  Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice , 2015, Journal of Pharmacokinetics and Pharmacodynamics.

[24]  Walter Schmitt,et al.  PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’ model , 2003 .

[25]  W. Nimmo,et al.  Novel drug delivery and its therapeutic application , 1989 .

[26]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[27]  I. Rietjens,et al.  Prediction of in vivo developmental toxicity of all-trans-retinoic acid based on in vitro toxicity data and in silico physiologically based kinetic modeling , 2014, Archives of Toxicology.

[28]  J A Wiltse,et al.  U.S. Environmental Protection Agency's revised guidelines for carcinogen risk assessment: evaluating a postulated mode of carcinogenic action in guiding dose-response extrapolation. , 2000, Mutation research.

[29]  Walter Schmitt,et al.  Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[30]  George Loizou,et al.  Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. , 2008, Regulatory toxicology and pharmacology : RTP.

[31]  T. Terasaki,et al.  Physiologically based pharmacokinetic model for cefazolin in rabbits and its preliminary extrapolation to man. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[32]  M. Klepser,et al.  Disposition of ofloxacin in female New Zealand white rabbits. , 1997, Journal of veterinary pharmacology and therapeutics.

[33]  N. Yamagishi,et al.  Using a single blood sample and inulin to estimate glomerular filtration rate in rabbits. , 2011, Journal of the American Association for Laboratory Animal Science : JAALAS.

[34]  Hugh A Barton,et al.  Case study illustrating the WHO IPCS guidance on characterization and application of physiologically based pharmacokinetic models in risk assessment. , 2013, Regulatory toxicology and pharmacology : RTP.

[35]  U. Hofmann,et al.  A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation. , 2015, Journal of pharmaceutical sciences.

[36]  The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide , 2014, European Journal of Drug Metabolism and Pharmacokinetics.

[37]  Xiaomei Zhuang,et al.  PBPK modeling and simulation in drug research and development , 2016, Acta pharmaceutica Sinica. B.

[38]  N Parrott,et al.  Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective , 2015, Clinical pharmacology and therapeutics.

[39]  N. Heinrich,et al.  Computational Chemistry in the Pharmaceutical Industry: From Childhood to Adolescence , 2015, ChemMedChem.

[40]  Wolfgang Weiss,et al.  A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks , 2011, Front. Physio..

[41]  H. Rochambeau,et al.  The rabbit. Husbandry, health and production. , 1986 .

[42]  Bienert Agnieszka,et al.  Pharmacokinetics and ocular disposition of paracetamol and paracetamol glucuronide in rabbits with diabetes mellitus induced by alloxan , 2012 .

[43]  Ioannis P. Androulakis,et al.  Quantitative Systems Pharmacology: A Framework for Context , 2016, Current Pharmacology Reports.

[44]  F. Theil,et al.  A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. , 2000, Journal of pharmaceutical sciences.

[45]  B. Blount,et al.  Application of Physiologically Based Pharmacokinetic Models in Chemical Risk Assessment , 2012, Journal of toxicology.

[46]  E. M. Renkin,et al.  Coupling of albumin flux to volume flow in skin and muscles of anesthetized rats. , 1988, The American journal of physiology.

[47]  A. Walubo,et al.  Interaction between valproic acid and acyclovir after intravenous and oral administration in a rabbit model. , 2007, Basic & clinical pharmacology & toxicology.

[48]  DE Mager,et al.  Development of Translational Pharmacokinetic–Pharmacodynamic Models , 2008, Clinical pharmacology and therapeutics.

[49]  Lukas Furst,et al.  Physiologically Based Pharmacokinetic Modeling Science And Applications , 2016 .

[50]  A. Edginton,et al.  Physiologically Based Pharmacokinetic Modeling and Simulation in Pediatric Drug Development , 2014, CPT: pharmacometrics & systems pharmacology.

[51]  Kannan Krishnan,et al.  Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment. , 2012, Advances in experimental medicine and biology.

[52]  Jörg Lippert,et al.  From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools , 2005, Expert opinion on drug metabolism & toxicology.

[53]  Hilda Witters,et al.  A European perspective on alternatives to animal testing for environmental hazard identification and risk assessment. , 2013, Regulatory toxicology and pharmacology : RTP.

[54]  W. Schmitt,et al.  A Physiologic Model for Simulating Gastrointestinal Flow and Drug Absorption in Rats , 2003, Pharmaceutical Research.

[55]  Thomas Hartung,et al.  Food for thought... on animal tests. , 2008, ALTEX.

[56]  E. Lim,et al.  The National Kidney Foundation Guideline on Estimation of the Glomerular Filtration Rate , 2003 .

[57]  N. Yamagishi,et al.  Estimation of glomerular filtration rate in rabbits by a single-sample method using iodixanol , 2012, Laboratory animals.

[58]  L. A. Fenu,et al.  Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs , 2007, Drug Metabolism and Disposition.

[59]  Hugh A Barton,et al.  Evaluation of physiologically based pharmacokinetic models for use in risk assessment , 2007, Journal of applied toxicology : JAT.

[60]  Walter Schmitt,et al.  Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. , 2008, Expert opinion on drug metabolism & toxicology.